- By Shuda Xia
General Electric Co. (GE), GlaxoSmithKline PLC (GSK), Ferrellgas Partners LP (FGP) and Crescent Point Energy Corp. (CPG) have declined to their three-year lows.
General Electric Co. (GE) declined to $17.82
The prices of General Electric Co. (GE) shares have declined to $17.82 on Dec. 15, which is only 2.0% above the 3-year low of $17.46.
-
Warning! GuruFocus has detected 4 Warning Signs with GE. Click here to check it out.
-
The intrinsic value of GE
General Electric Co. is an American international conglomerate corporation and operates through multiple segments, including Power & Water, Oil and Gas, Aviation, Healthcare, and Transportation. The company has over 305,000 employees as of 2015 and ranked among the Fortune 500 as the 4th largest firm in the United States as of 2017.
General Electric Co. has a market cap of $154.54 billion; its shares were traded around $17.82 with a P/E ratio of 22.56 and P/S ratio of 1.26. The trailing 12-month dividend yield of General Electric Co. stocks is 5.38%. The forward dividend yield of General Electric Co. stocks is 4.76%.
On Dec. 13 General Electric Co. announced agreements to provide 270 MW of wind energy capacity to Wind Energy Holding, a member of Thailand"s KPN Group, for the Theparak Wind Farm in central Thailand. The electricity generated is enough to power the equivalent of more than 120,000 local homes. General Electric Co. is set to provide a total of ninety 3.0-137 wind turbines with 156.5m hybrid towers, making those the tallest turbines the company has installed outside of Europe.
GlaxoSmithKline PLC (GSK) declined to $34.99
The prices of GlaxoSmithKline PLC (GSK) shares have declined to $34.99 on Dec. 15, which is only 1.2% above the 3-year low of $34.58.
GlaxoSmithKline PLC is a British pharmaceutical company formed from the merger of Glaxo Wellcome and SmithKline Beecham in 2000. In 2015 it was the world"s sixth largest pharmaceutical company. The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. Some of its top selling products include Advair, Avodart, Augmentin, Lovaza and Flovent.
GlaxoSmithKline PLC has a market cap of $83.77 billion; its shares were traded around $34.99 with a P/E ratio of 27.34 and P/S ratio of 2.09. The trailing 12-month dividend yield of GlaxoSmithKline PLC stocks is 5.92%. The forward dividend yield of GlaxoSmithKline PLC stocks is 5.72%.
On Dec. 14 GlaxoSmithKline PLC announced the submission of a regulatory application to the Australian Therapeutics Good Administration seeking approval of single-dose tafenoquine treatment for radical cure, or prevention of relapse, of malaria. Approval of tafenoquine by the TGA will help facilitate registrations in countries where malaria is endemic.